9:10 AM
 | 
Nov 16, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA approves Antares' Xyosted testosterone replacement therapy

FDA approved in October Xyosted from Antares Pharma Inc. (NASDAQ:ATRS) as a testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >